Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it.

The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...